Clinical Trials
8 trialsNCT03625323 2026-04-22
TACTI-002
Immutep S.A.S.
Phase 2 Completed
NCT06726265 2026-03-18
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)
Immutep S.A.S.
Phase 3 Active not recruiting
NCT04811027 2025-12-11
TACTI-003
Immutep S.A.S.
Phase 2 Completed
NCT05747794 2024-12-17
AIPAC-003
Immutep S.A.S.
Phase 2/3 Active not recruiting
NCT04252768 2023-03-22
AIPAC-002
Immutep S.A.S.
Phase 1 Withdrawn
NCT02676869 2019-12-18
TACTI-mel
Immutep Australia Pty. Ltd.
Phase 1 Completed
NCT00349934 2010-01-07
IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma
Immutep S.A.S.
Phase 1 Completed
NCT00351949 2010-01-07
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Immutep S.A.S.
Phase 1 Completed